X. Schwangerschaftsbedingte Trophoblasterkrankungen

1. Bagshawe K.D.: Treatment of high-risk choriocarcinoma. J Reprod Med 1984; 29:813
2. Berkowitz R.S., Goldstein P.D.: Chorionic tumors. New Engl J Med 1996; 335:1740-748
3. Eiriksson L., Wells T., Steed H., Schepansky A., Capstick V. et al.: Combined methotrexate-dactinomycin: An effective therapy for low-risk gestational trophoblastic neoplasia. Gynecol Oncol 2011; E-pub ahead of print
4. FIGO Oncology Committee. FIGO staging for gestational trophoblastic neoplasia 2000. Int J Gynaecol Obstet 2002; 77:285
5. Goldstein P.D., Zantan-Przybysz I.V., Bernstein M.R., Berkowitz R.S.: Revised FIGO staging system for gestational trophoplastic tumors. J Reprod Med 1998; 1:37-43
6. Hassadia A., Gillespie A., Tidy J., Everard R.G.N.J, Wells M., Coleman R., Hancock B.: Placental site trophoblastic tumour: clinical features and management. Gynecol Oncol 2005; 99:603
7. Kohorn E.I.: The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: Description and critical assessment. Int J Gynecol Cancer 2001; 11:73
8. Lorigan P.C., Sharma S., Bright N., Coleman R.E., Hancock B.W.: Characteristics of women with recurrent molar pregnancies. Gynecol Oncol 2000 Sep; 78 (3 Pt 1):288-92
9. Matsui H., Iitsuka Y., Suzuka K., Yamazawa K., Mitsuhashi A., Sekiya S.: Salvage chemotherapy for high risk gestational trophoblastic tumor. J Reprod Med 2004; 49:438
10. Moodley M., Tunkyi K., Moodley J.: Gestational trophoblastic syndrome: an audit of 112 patients. A South African experience. Int J Gynecol Cancer 2003 Mar-Apr; 13 (2):234-9
11. Mutch D.G., Soper J.T., Babcock C.J., Clarke-Pearson D.L., Hammond C.B.: Recurrent gestational trophoblastic disease. Experience of the Southeastern Regional Trophoblastic Disease Center. Cancer 1990; 66:978-982
12. Newlands E.S., Bower M., Fisher R.A., Paradinas F.J.: Management of placental site trophoblastic tumors. J Reprod Med 1998; 1:53-59
13. Newlands E.S., Mulholland P.J., Holden L., Seckl M.J., Rustin G.J.: Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. J Clin Oncol 2000 Feb; 18 (4):854-9
14. Osborne R.J., Filiaci V., Schink J.C., Mannel R.S., Secord A.A. et al.: Phase III Trial of Weekly Methotrexate or Pulsed Dactinomycin for Low-Risk Gestational Trophoblastic Neoplasia: A Gynecologic Oncology Group Study. J Clin Oncol 2011; 29:825-31.
15. Powles T., Savage P.M., Stebbing J., Short D., Young A., Bower M.A., Pappin C., Schmid P., Seckl M.J.: A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia. Br J Cancer 2007 Mar 12; 96 (5):732-7
16. Soper J.T.: Chemotherapy for gestational trophoblastic disease. Ed. by Deppe G., Baker W.: Gynecologic oncology. Principles and practice of chemotherapy 1999; 268-289
17. Soper J.T.: Role of surgery and radiation therapy in the management of gestational trophoblastic disease. Best Pract Res Clin Obstet Gynaecol 2003 Dec; 17:943-957
18. Xiang Y., Sun Z., Wan X., Yang X.: EMA/EP chemotherapy for chemorefractory gestational trophoblastic tumor. J Reprod Med 2004 Jun; 49 (6):443-6